<DOC>
	<DOCNO>NCT02296658</DOCNO>
	<brief_summary>The aim phase II trial evaluate feasibility , efficacy tolerability intensity-modulated radiotherapy combine S-1 base chemotherapy patient pathologically positive lymph node completely resect gastric cancer . Furthermore , investigator seek compare dosimetric difference volumetric-modulated arc therapy ( VMAT ) , Tomotherapy intensity-modulated radiotherapy ( IMRT ) techniques treatment plan gastric cancer adjuvant radiotherapy .</brief_summary>
	<brief_title>A Phase II Study Postoperative S-1-Based Chemoradiotherapy Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Pathologically proven positive lymph node gastric adenocarcinoma patient undergo R0 resection Any prior chemotherapy allow protocol No distant metastasis liver , lung , ,bone , central nervous system ( CNS ) , peritoneal transplantation No prior abdominal pelvic radiotherapy Karnofsky performance status ( KPS ) â‰¥ 70 , predictive life span le 6 month Patients must normal organ marrow function define : Leukocytes great equal 3,000 G/L Platelets : great equal 100,000/mm3 Hemoglobin : great equal 10g/L Total bilirubin : within normal institutional limit AST/ALT : less equal 1.5 time upper limit Creatinine within normal upper limit Informed consent Patients cancer history except cervical carcinoma situ nonmalignant melanoma skin cancer With distant metastasis liver , lung , ,bone , CNS , peritoneal transplantation History allergic reaction attribute similar chemical biologic complex S1 Uncontrolled illness include , limited , active infection , symptomatic heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness History myocardial infarction within past 6 month history ventricular arrhythmia History prior radiation abdomen Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>